ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) has announced that researchers have shown that Tß4 has more extensive beneficial effects on the myocardium after heart attack than previously reported. The research team also confirmed previous reports that Tß4 activates the Akt survival kinase and protects cardiac muscle cells from apoptosis (programmed cell death), that the infarct sizes were smaller and cardiac function significantly improved in mice receiving Tß4, and that Tß4-treated mice had a significant reduction in cardiac fibrosis (scarring) due to the reduction of collagen expression.
